Understand the source comparison
Comparison: ARA-290 Stacking Protocols by Research Goal
ARA-290 + BPC-157 IRR anti-inflammatory + VEGF angiogenesis and axonal growth ARA-290 4mg/day, BPC-157 500mcg twice daily ARA-290 morning, BPC-157 afternoon/evening (4–6 hour gap) Neuropathy, nerve injury, diabetic complications Strongest evidence for neuropro
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA-290 + BPC-157
- IRR anti-inflammatory + VEGF angiogenesis and axonal growth
- ARA-290 4mg/day, BPC-157 500mcg twice daily
- ARA-290 morning, BPC-157 afternoon/evening (4–6 hour gap)
- Neuropathy, nerve injury, diabetic complications
- Strongest evidence for neuroprotection. Complementary pathways with minimal overlap
- ARA-290 + TB-500
- IRR tissue protection + actin-mediated cell migration and wound healing
- ARA-290 4mg/day, TB-500 5mg twice weekly
- Separate by 4+ hours on TB-500 dosing days
- Tendon/ligament repair, post-surgical recovery
- Effective for structural tissue repair. Long TB-500 half-life provides sustained coverage
- ARA-290 + GHRP-2
- IRR repair signaling + endogenous GH pulse for IGF-1 upregulation
- ARA-290 4mg/day, GHRP-2 100–200mcg 3x/day
- ARA-290 morning or evening, GHRP-2 pre-meal
- Body recomposition, recovery enhancement, aging research
- No receptor competition. Works well when recovery and anabolism are both goals
- ARA-290 + Thymosin Alpha-1
- IRR inflammation control + immune T-cell modulation
- ARA-290 4mg/day, Tα1 1.6mg 3x/week
- Separate by 4+ hours
- Autoimmune conditions, post-viral recovery, chronic inflammation
- Complementary immune pathways. Avoid injection site overlap
- ARA-290 + EPO
- Overlapping CD131 binding. Potential competitive inhibition
- Not recommended
- N/A
- Severe anemia with neuropathy (medical supervision only)
- No synergy documented. EPO already activates overlapping pathways